Answers are grounded in this paper and cite their sources.
Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and cell types makes functional investigation challenging. We used induced pluripotent stem cells from 49 individuals to generate heterogeneous differentiating cultures (HDCs) containing multiple cell types, treated them with five ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib) for 24 hours, and characterized transcriptional responses using single-cell RNA sequencing. These responses showed cell-type-specific and shared transcriptional effects. Integrating gene expression with individual genotypes, we identified 4,371 expression quantitative trait loci (eQTLs) across 21 cell types, including 2,137 response eQTLs whose regulatory effects differ between untreated and drug-treated cells. These results nominate candidates for future studies of ALK inhibitor toxicity.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: